COVID-19 Ag Detection Kit

(Immunofluorescence-Based)



Further information can be obtained from local distributor, or by contacting Technical Support on: Tel: (+852) 3502 2780 Email: info@immunodiagnostics.com.hk

IMPORTANT: Read the instruction manual before use. For the best performance, direct nasal swabs should be tested preferably as soon as possible after collection.

PROCEDURE CARD

ASSAY PROCEDURE

Specimen Preparation Procedure:

(Nasal swab)

- •Transfer 20 drops (- $500~\mu L$) of sample lysis buffer into an extraction tube using a transfer pipet.
- •Insert the swab into an extraction tube. While squeezing the buffer tube, stir the swab more than 5 times and wait for 1 minute.
- •Squeeze the wall of the tube to extract the liquid from the swab.
- •Press the nozzle cap tightly onto the tube.



Analysis of Specimen:

- •Apply 2 drops ($\sim 80~\mu L$) of the extracted specimen to the specimen well of the test strip.
- •Read the test result in 20 minutes.

Dry Immunofluorescence Analyzer Run Test with FIC-H1W

- · Turn on the machine
- Select "QUICK TEST" or "STANDARD TEST".
- Input patient information, including Name, Age, Sex.
- Insert the prepared test strip into the machine.
- Click "QUICK TEST" or "STANDARD TEST".
- The test result (RS) will be displayed on the screen within 5 seconds.
- •Click "NEW "to start a new test or Click "MENUS" to return to the homepage.

The test result is determined by T/C value. The following information will be displayed on the screen.


Value: T/C -ration of fluorescent signal from test line and control line. T/C higher than 0.15 is positive, and T/C lower than 0.15 is negative (including 0.15).

Result (RS): "+"=Weak Positive; "++"=Medium Positive; "+++"=Strong Positive; "-"=Negative

Reference 0-0.15: T/C range for negative results

| Positive | | | Negative |
|-------------------|------------------|-----------|----------|
| Weak | Medium | Strong | Negative |
| 0.25 ≥ T/C > 0.15 | 2.5 ≥ T/C > 0.25 | T/C > 2.5 | ≤ 0.15 |
| + | ++ | +++ | - |

Note: If the result is invalid, the test should be repeated.



Dry immunofluorescence analyzer

Do not interpret the result 25 minutes.

RESULT INTERPRETATION

The fluorescent signal from test line and control line cannot be seen with the naked eyes. A dry immunofluorescence analyzer should be used for reading the result.



ImmunoDiagnostics Limited

5F, Biotech Centre 2 (11W), No. 11 Science Park West Avenue, Hong Kong Science Park, Shatin. NT, Hong Kong E-mail: info@immunodiagnostics.com.hk

Tel: (+852) 3502 2780; Fax: (+852)3502 2781

EC REP SUNGO Europe B.V.

VAT: NL857821659B01

Address: Olympisch Stadion 24, 1076DE Amsterdam, Netherlands Tel/Fax: +31 (0) 2021 11106 E-mail: ec.rep@sungogroup.com



ImmunoDiagnostics Limited

COVID-19 Ag Detection Kit

(Immunofluorescence-Based) Catalog Numbers 41A255

(Please read this instruction manual before use.) **WARNING!** Wear appropriate protective eyewear, clothing, and gloves.

INTENDED USE

COVID-19 Ag Detection Kit (Immunofluorescence-Based) is a lateral flow test for the detection of SARS-CoV-2 Nucleocapsid protein (NP) in direct nasal swabs from individuals suspected of COVID-19 within the first seven days of symptom onset, which is intended to be used by healthcare professionals. This test is intended for a Point-of-Care setting.

SUMMARY

The spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has caused a worldwide COVID-19 pandemic. Rapid identification and isolation of COVID-19 patients and asymptomatic carriers is the main strategy to contain this pandemic.

COVID-19 Ag Detection Kit (Immunofluorescence-Based) is a rapid flow immunoassay for the qualitative detection and diagnosis of SARS-CoV-2 from nasal swab.

ASSAY PRINCIPLE

COVID-19 Ag Detection Kit (Immunofluorescence-Based) is an immunochromatographic membrane assay that uses highly-specific monoclonal antibodies to detect SARS-CoV-2 NP from nasal swab specimens. An anti-SARS-CoV-2 NP monoclonal antibody is pre-coated on the nitrocellulose membrane as the test line, while the chicken IgY is pre-coated as the control line.

During the test, the sample reacts with another fluorescent microspheres-conjugated anti-SARS-CoV-2 NP monoclonal antibody in the conjugation pad. The fluorescent microspheres-conjugated goat anti-chicken IgY in the conjugation pad serves as the control particles. The sample migrates upward on the membrane by capillary action and reacts with the test line and control line. The result can be read within 15-20 minutes using a dry immunofluorescence analyzer or a blue LED light. If the sample contains SARS-CoV-2 NP, a fluorescent signal can be detected from the test line, revealing a positive result. If the sample does not contain SARS-CoV-2 NP, no fluorescent signal can be detected from the test line, indicating a negative result. As a procedural control, a fluorescent signal can be detected from the control line.

REAGENTS AND MATERIALS

- 1. COVID-19 Ag strip (20 tests/kit) One aluminum pouch with a strip
- 2. Sample lysis buffer (10 mL)
- 3. Extraction Tubes (20 tubes)
 The tubes and nozzle caps come in a zip-locked plastic bag
- 4. Swabs (20 nasal swabs)
 Individually pouched flocked swabs
- 5. Transfer Pipets (20 transfer pipet)
 Individually pouched plastic transfer pipet
- 6. Positive Control Swab: Non-infectious recombinant SARS-CoV-2 nucleocapsid antigen dried onto a swab
- 7. Negative Control Swab: The use of sterile swab to ensure a negative result is obtained
- 8. Product Insert
- 9. Procedure Card

OTHER MATERIALS REQUIRED, BUT NOT PROVIDED

- 1. Timer or other equipment for time recording.
- 2. If clinical samples other than nasal secretions need to be measured, other kinds of swab may be required (such as throat swabs).
- 3. Dry immunofluorescence analyzer (FIC-HIW, ImmunoDiagnostics Ltd. or UNT2000I, Guangdong Uniten Biotechnology).

PRECAUTIONS

- All reagents are for *in vitro* research use only.
- All operations linked to the use of the test must be performed following Good Laboratory Practices (GLP).
- -All reagents should be equilibrated to room temperature before use.
- Avoid touching nitrocellulose membrane with your fingers.
- Wears gloves, mask FFP2 or FFP3, lab glasses when handling samples. Otherwise, run the test under a Laminar Air Flow cabinet.
- Reagents cannot be mixed from different kits.
- -The quality of expired reagents cannot be guaranteed if reagents are not stored under required conditions as indicated in the manual.
- Do not use the strip if the pouch is damaged or the seal is broken.
- Do not reuse the used test strip.
- Inadequate or inappropriate sample collection, storage, and transport may yield false test results.
- INVALID RESULTS may occur when an insufficient volume of sample lysis buffer is added to the test strip.
- Do not smoke, eat, or drink in areas in which specimens or kit reagents are handled.



STORAGE

- Store kit at 4-30 °C. The Kit is stable until the expiration date marked on the package label.
- Avoid freezing strips and buffer.
- The test strip is stable until the expiry date only if it has not been opened and kept in the sealed aluminum pouch.
- Do not open the sealed pouch until use. Once opened, the strip should be used within 1 hour.

QUALITY CONTROL

Good laboratory practice suggests the use of positive and negative controls to ensure the test reagents are working and the test is correctly performed. Both a **Positive Control Swab** and a **Negative Control Swab** are included in this kit, which can be used to monitor the entire assay. Test these swabs once with each new shipment received and each untrained operator. Further controls may be tested to fulfill the need from local regulations, accrediting groups, or lab's standard Quality Control procedures.

If the correct control results are not obtained, do not perform patient tests or report patient results. Contact Technical Support during business hours before testing patient specimens.

SPECIMEN COLLECTION AND HANDLING

Improper specimen collection or sample handling/storage/transport may yield wrong results.

Nasal Swab

To collect a nasal swab sample, carefully insert the swab less than one inch (about 2 cm) into the nostril parallel to the palate until resistance is met at turbinate. Firmly sample the nasal wall by rotating the swab in a circular path against the nasal wall 5 times or more for a total of 10 seconds. Slowly removing the swab, insert it into the other nostril and repeat the process.

Sample Transport and Storage

For the best performance, direct nasal swabs should be tested preferably as soon as possible after collection. Based on data generated with SARS-CoV-2 COVID-19 Ag Detection Kit (Immunofluorescence-Based), nasal swabs are stable for up to 48-hours at 2~8°C. For long term storage, samples can be stored at -60~80°C up to 1 year.

TEST PROCEDURE

Preparation of Test:

Equilibrate kit components in unopened packaging to room temperature (15-30 °C) before starting the test. Open the test strip just prior to use, lay it flat. Clearly label the extraction tube with patient's information.


Assay Procedure:

- 1. Transfer 20 drops (~500μL) of sample lysis buffer into an extraction tube using a transfer pipette.
- 2. Insert the swab into an extraction tube. While squeezing the buffer tube, stir the swab more than 5 times and wait for 1 minute.
- 3. Squeeze the wall of the tube to extract the liquid from the swab.
- 4. Press the nozzle cap tightly onto the tube.



Analysis of Specimen:

- 5. Apply 2 drops (\sim 80 μ L) of the extracted specimen to the specimen well of the test strip.
- 6. Read the test result in 15-20 minutes.



Do not interpret the result after 25 minutes.

INTERPRETATION OF TEST RESULT

The fluorescent signal from test line and control line cannot be seen with the naked eyes. A dry immunofluorescence analyzer should be used for reading the result.

Dry immunofluorescence analyzer Run Test with FIC-H1W QUICK TEST/STANDARD TEST Mode

a. Turn on the machine



- b. Select "QUICK TEST" or "STANDARD TEST".
- c. Input patient information, including Name, Age, Sex. As shown in the example below.



- d. Insert the prepared test strip into the machine.
- e. Click "QUICK TEST" or STANDARD TEST.
- f. The test result (RS) will be displayed on the screen within 5 seconds.
- g. Click "NEW" to start a new test or Click "MENUS" to return to the homepage.

The test result is determined by T/C value. The following information will be displayed on the screen. The results can be automatically printed if a printer is connected.

Value: T/C-ratio of fluorescent signal from test line and control line. T/C higher than 0.15 is positive, and T/C lower than 0.15 is negative (including 0.15).

Result (RS): "+"=Weak Positive; "++"=Medium Positive; "+++"=Strong Positive; "-"=Negative Reference 0-0.15: T/C range for negative results



Interpretation of result

| Positive | | | Negative |
|-------------------|------------------|-----------|----------|
| Weak | Medium | Strong | Negative |
| 0.25 ≥ T/C > 0.15 | 2.5 ≥ T/C > 0.25 | T/C > 2.5 | ≤ 0.15 |
| + | ++ | +++ | - |

Note: If the result is invalid, the test should be repeated.



For example: This display shows an invalid result.

LIMITATION OF TEST

- A negative test result may occur if the level of the extracted antigen in a specimen is below the

sensitivity of the test or if a poor-quality specimen is obtained.

- Negative test results do not rule out the possibility of SARS-CoV-2 infection, which should be further confirmed by RT-PCR.
- Positive test results do not rule out co-infections with other pathogens.
- COVID-19 Ag Detection Kit (Immunofluorescence-Based) was evaluated using the procedures provided in this product insert only. Any modification of procedures may affect the performance of the test.
- The test result must always be evaluated with other data available to the physician.
- The performance of this device has not been assessed in a population vaccinated against COVID-19.

WASTE DISPOSAL

- Dispose of gloves, swabs, extraction tubes, used strips in accordance with GLP.
- Each user is responsible for the management of any waste produced and must ensure that it is disposed of in accordance with the applicable legislation.

PERFORMANCE CHARACTERISTICS

Clinical Performance

The COVID-19 Ag Detection Kit (Immunofluorescence -Based) has been evaluated with specimens obtained from COVID-19 patients (within 7 days of onset). Tests were conducted by operators who are representative of the intended users. Patients who presented within 7 days of symptom onset were included in the primary analysis. The results show that the COVID-19 Ag Detection Kit (Immunofluorescence-Based) has high sensitivity and specificity.

| specifically. | | | | |
|---|----------|----------|----------|-------|
| Reagents | | RT-PCR | | Total |
| | | Positive | Negative | TOTAL |
| COVID-19 Ag | Positive | 79 | 13 | 92 |
| Detection Kit | Negative | 5 | 412 | 417 |
| Total | | 84 | 425 | 509 |
| Positive Agreement: 79/84 94.03% (95%CI: 88.47%-98.96%) | | | | |
| Negative Agreement: 412/425 96.94% (95%CI: 94.12%-98.35%) | | | | |

Relative Sensitivity: 94.03%, 95% CI: 88.47%~98.96%; Relative Specificity: 96.94%, 95% CI: 94.12%~98.35%.

For initial validation, the COVID-19 Ag Detection Kit (Immunofluorescence -Based) has also been used to test the presence of SARS-CoV-2 NP in serum sample from 58 COVID-19 patients (1:10 dilution), and the result show that half of the patients are NP positive.

Analytical Performance Analytical Sensitivity

The limit of detection was determined by evaluating different concentration of inactivated SARS-CoV-2 virus, which was diluted in natural nasal swab matrix pool to generate virus dilutions for test.

| TCID50/ml | Number Positive/Total | % Detected |
|-----------|-----------------------|------------|
| 93.3 | 19/20 | 95 |

The analytical sensitivity of COVID-19 Ag Detection Kit (Immunofluorescence-Based) is 93.3 $TCID_{50}/ml$.

High Dose Hook Effect

No high dose hook effect was noted when tested with up to a concentration of 2.8×10⁶ TCID₅₀ /ml of inactivated SARS-CoV-2 virus with COVID-19 Ag Detection Kit (Immunofluorescence-Based).

Endogenous Substances Interference Test

Substances with test concentration in the table do not affect the performance of COVID-19 Ag Detection Kit (Immunofluorescence-Based).

| Substance | Concentration | Substance | Active Ingredient | Concentration |
|--------------------------|---------------|-------------------|-------------------|---------------|
| Mucin | 2% w/v | OTC Nasal Drop | Phenylephrine | 12% v/v |
| Benzocaine | 5 mg/ml | OTC Nasal Spray 1 | Cromolyn | 15% v/v |
| Tobramycin | 5 ug/ml | OTC Nasal Spray 2 | Oxymetazoline | 15% v/v |
| Oseltamivir phosphate | 10 mg/ml | OTC Nasal Spray 3 | Fluconazole | 5% w/v |
| Arbidol | 5 mg/ml | OTC Homeopathic | | / |
| Triamcinolone | 10 mg/ml | Nasal Spray 1 | Zincum gluconium | 5% w/v |
| Mupirocin | 10 mg/ml | OTC Homeopathic | Allestel | 400//. |
| Zanamivir | 5 mg/ml | Nasal Spray 2 | Alkalol | 10% v/v |
| Ribavirin | 5 mg/ml | OTC Homeopathic | Fluticasone | |
| Dexamethasone | 5 mg/ml | Nasal Spray 3 | Propionate | 5% v/v |

Cross Reactivity and Microbial Interference

Cross reactivity and potential interference of COVID-19 Ag Detection Kit (Immunofluorescence-Based) was tested in microorganisms listed in the table that may be present in the nasal cavity. No cross reactivity or interference was noted when tested at current concentration presented in the table.

| Type | Human Cross Reactant | Test Concentration | |
|-------------|-----------------------------|--|--|
| | Human coronavirus HKU1 | 1×10 ⁵ TCID ₅₀ /ml | |
| | Human coronavirus OC43 | 1×10 ⁵ TCID ₅₀ /ml | |
| Coronavirus | Human coronavirus NL63 | 1×10 ⁵ TCID ₅₀ /ml | |
| | Human coronavirus 229E | 1×10 ⁵ TCID ₅₀ /ml | |
| | MERS-coronavirus | 10 μg/ml | |
| | SARS-coronavirus | 10 μg/ml | |
| | Rhinovirus | 1×10 ⁵ PFU/ml | |
| | Adenovirus | 1×10 ⁵ TCID ₅₀ /ml | |
| | Human Metapneumovirus | 1×10 ⁵ TCID ₅₀ /ml | |
| Virus | Parainfluenza 1 | 1×10 ⁵ TCID ₅₀ /ml | |
| | Parainfluenza 2 | 1×10 ⁵ TCID ₅₀ /ml | |
| | Parainfluenza 3 | 1×10 ⁵ TCID ₅₀ /ml | |
| | Parainfluenza 4 | 1×10 ⁵ TCID ₅₀ /ml | |
| | Influenza A | 1×10 ⁵ TCID ₅₀ /ml | |
| | Influenza B | 1×10 ⁵ TCID ₅₀ /ml | |
| | Enterovirus | 1×10 ⁵ TCID ₅₀ /ml | |
| | Respiratory syncytial virus | 1×10 ⁵ PFU/ml | |

| Type | Human Cross Reactant | Test Concentration |
|-------------------------|-------------------------------|----------------------------|
| | Bordetella pertussis | 1×10 ⁶ cells/ml |
| | Chlamydia pneumoniae | 1×10 ⁶ IFU/ml |
| | Haemophilus influenzae | 1×10 ⁶ cells/ml |
| | Legionella pneumoniae | 1×10 ⁶ cells/ml |
| Bacteria | Mycoblasma pneumoniae | 1×10 ⁶ U/ml |
| Dacteria | Streptococcus pneumoniae | 1×10 ⁶ cells/ml |
| | Streptococcus pyogenes | 1×10 ⁶ cells/ml |
| | Mycobacterium tuberculosis | 1×10 ⁶ cells/ml |
| | Staphylococcus aureus | 1×10 ⁶ org/ml |
| | Staphylococcus epidermidis | 1×10 ⁶ cells/ml |
| Yeast | Candida albicans | 1×10 ⁶ cells/ml |
| Pooled human nasal wash | | - |

Note: TCID50 -Median Tissue Culture Infectious Dose; PFU-Plaque Forming Unit

SYMBOLS

| *** | Manufacturer | CE | EC Declaration of Conformity |
|-------------|----------------------------|-------------|---------------------------------|
| \subseteq | Expiry date | i | Consult Instruction |
| LOT | Lot number | 1 | Store |
| REF | Catalog number | \triangle | Caution |
| IVD | In Vitro Diagnostic Device | EC REP | Name and Address of EU REP |

ImmunoDiagnostics Limited

5F, Biotech Centre 2 (11W), No. 11 Science Park

West Avenue, Hong Kong Science Park, Shatin. NT, Hong Kong E-mail: info@immunodiagnostics.com.hk

Tel: (+852) 3502 2780; Fax: (+852)3502 2781

EC REP SUNGO Europe B.V.

VAT NL857821659B01

Address: Olympisch Stadion 24, 1076DE Amsterdam, Netherlands Tel/Fax: +31 00 2021 11106 E-mail: ec.rep@sungogroup.com